Muscle diseases come in a variety of forms. Among the more common conditions are muscle wasting, which can occur in cancer patients and the elderly. But there are also hundreds of genetically caused muscle diseases as well as local muscle defects that altogether affect more than 15 million in Europe.

MyoPax are a pre-spinout group at the Max Delbrueck Center and Charité – Universitätsmedizin in Berlin, Germany, whose work is suppored by https://www.spark-bih.de/ (SPARK Berlin). They are developing a stem cell based approach to treat muscular disease by regenerating tissue and have already established a biobank to store treated stem cells.

In this episode of https://www.lifescienceorg.com/bioinnovation (BioInnovation Spotlight @ LifeScience ORG) Verena talks about the impact of muscle disease, MyoPax's technology and how it works, and their plans to spin out.